A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment

Exclusion Criteria

• •History of blood coagulation disorders or hypercoagulability.
• •Current use of anticoagulant therapy. Use of antiplatelet drugs (e.g., aspirin or clopidogrel) is acceptable.
• •Prior hypersensitivity reaction to any human blood product or any IV infusion.
• •Treatment with any human blood product, including transfusions and IV immunoglobulin, during the 6 months prior to screening.
• •History of immunoglobulin A or haptoglobin deficiency; stroke, anaphylaxis, or thromboembolic complications of IV immunoglobulins.
• •Heart disease, as evidenced by myocardial infarction, unstable, new onset or severe angina, or congestive heart failure in the 6 months prior to dosing
• •Hemoglobin \< 10 g/dL in women and \< 11 g/dL in men.